WISAM SALMAN: Open Payments
NPI 1972706133 · MARSHALL, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$856 in 38 payments from 9 companies in 2025. Trend: 2023 $633 · 2024 $907 · 2025 $856
Food & beverage: $856
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 7 | $170 |
| Teva Pharmaceuticals USA, Inc. | 9 | $141 |
| Axsome Therapeutics, Inc. | 4 | $138 |
| ABBVIE INC. | 5 | $120 |
| Neurocrine BioSciences, Inc. | 4 | $104 |
| E.R. Squibb & Sons, L.L.C. | 4 | $83 |
| Janssen Pharmaceuticals, Inc | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
Products named: ARISTADA, Auvelity, UZEDY, VRAYLAR, INGREZZA, COBENFY, INVEGA SUSTENNA, FANAPT.
Industry payments across MI — which companies pay providers there.
